Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.90
SVA's Cash to Debt is ranked lower than
73% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. SVA: 1.90 )
Ranked among companies with meaningful Cash to Debt only.
SVA' s 10-Year Cash to Debt Range
Min: 0.48  Med: 2.35 Max: N/A
Current: 1.9
Equity to Asset 0.59
SVA's Equity to Asset is ranked lower than
60% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SVA: 0.59 )
Ranked among companies with meaningful Equity to Asset only.
SVA' s 10-Year Equity to Asset Range
Min: 0.41  Med: 0.57 Max: 0.64
Current: 0.59
0.41
0.64
Interest Coverage 0.14
SVA's Interest Coverage is ranked lower than
99% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SVA: 0.14 )
Ranked among companies with meaningful Interest Coverage only.
SVA' s 10-Year Interest Coverage Range
Min: 0.14  Med: 15.63 Max: 9999.99
Current: 0.14
0.14
9999.99
F-Score: 2
Z-Score: 2.58
M-Score: -2.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -3.96
SVA's Operating margin (%) is ranked higher than
66% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. SVA: -3.96 )
Ranked among companies with meaningful Operating margin (%) only.
SVA' s 10-Year Operating margin (%) Range
Min: -35600  Med: -27.17 Max: 50.06
Current: -3.96
-35600
50.06
Net-margin (%) -5.28
SVA's Net-margin (%) is ranked higher than
64% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. SVA: -5.28 )
Ranked among companies with meaningful Net-margin (%) only.
SVA' s 10-Year Net-margin (%) Range
Min: -39700  Med: -25.47 Max: 23.7
Current: -5.28
-39700
23.7
ROE (%) -2.47
SVA's ROE (%) is ranked higher than
70% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. SVA: -2.47 )
Ranked among companies with meaningful ROE (%) only.
SVA' s 10-Year ROE (%) Range
Min: -50.22  Med: -2.21 Max: 33.16
Current: -2.47
-50.22
33.16
ROA (%) -1.34
SVA's ROA (%) is ranked higher than
72% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. SVA: -1.34 )
Ranked among companies with meaningful ROA (%) only.
SVA' s 10-Year ROA (%) Range
Min: -310.16  Med: -4.73 Max: 17.45
Current: -1.34
-310.16
17.45
ROC (Joel Greenblatt) (%) 1.27
SVA's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. SVA: 1.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1668.29  Med: -23.24 Max: 137.02
Current: 1.27
-1668.29
137.02
Revenue Growth (3Y)(%) 2.80
SVA's Revenue Growth (3Y)(%) is ranked higher than
53% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. SVA: 2.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SVA' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 27.30 Max: 81.7
Current: 2.8
0
81.7
EBITDA Growth (3Y)(%) 12.90
SVA's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.50 vs. SVA: 12.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SVA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -27.50 Max: 174.1
Current: 12.9
0
174.1
» SVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

SVA Guru Trades in Q2 2014

Jim Simons 1,175,000 sh (+13.89%)
Chris Davis 1,250,546 sh (+0.51%)
» More
Q3 2014

SVA Guru Trades in Q3 2014

Jim Simons 1,266,000 sh (+7.74%)
Chris Davis Sold Out
» More
Q4 2014

SVA Guru Trades in Q4 2014

Jim Simons 1,176,362 sh (-7.08%)
» More
Q1 2015

SVA Guru Trades in Q1 2015

Jim Simons 1,186,200 sh (+0.84%)
» More
» Details

Insider Trades

Latest Guru Trades with SVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.22
SVA's P/B is ranked higher than
78% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. SVA: 2.22 )
Ranked among companies with meaningful P/B only.
SVA' s 10-Year P/B Range
Min: 0.73  Med: 2.34 Max: 11.83
Current: 2.22
0.73
11.83
P/S 4.66
SVA's P/S is ranked higher than
77% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. SVA: 4.66 )
Ranked among companies with meaningful P/S only.
SVA' s 10-Year P/S Range
Min: 0.98  Med: 4.47 Max: 26.4
Current: 4.66
0.98
26.4
EV-to-EBIT 207.85
SVA's EV-to-EBIT is ranked lower than
92% of the 225 Companies
in the Global Biotechnology industry.

( Industry Median: 29.73 vs. SVA: 207.85 )
Ranked among companies with meaningful EV-to-EBIT only.
SVA' s 10-Year EV-to-EBIT Range
Min: -1028.5  Med: -4.30 Max: 555.1
Current: 207.85
-1028.5
555.1
Shiller P/E 224.42
SVA's Shiller P/E is ranked lower than
89% of the 107 Companies
in the Global Biotechnology industry.

( Industry Median: 48.91 vs. SVA: 224.42 )
Ranked among companies with meaningful Shiller P/E only.
SVA' s 10-Year Shiller P/E Range
Min: 15.09  Med: 53.24 Max: 290
Current: 224.42
15.09
290
Current Ratio 2.20
SVA's Current Ratio is ranked lower than
73% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. SVA: 2.20 )
Ranked among companies with meaningful Current Ratio only.
SVA' s 10-Year Current Ratio Range
Min: 1.16  Med: 2.56 Max: 6.15
Current: 2.2
1.16
6.15
Quick Ratio 1.86
SVA's Quick Ratio is ranked lower than
72% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. SVA: 1.86 )
Ranked among companies with meaningful Quick Ratio only.
SVA' s 10-Year Quick Ratio Range
Min: 0.85  Med: 2.28 Max: 5.43
Current: 1.86
0.85
5.43
Days Inventory 435.63
SVA's Days Inventory is ranked lower than
95% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. SVA: 435.63 )
Ranked among companies with meaningful Days Inventory only.
SVA' s 10-Year Days Inventory Range
Min: 103.07  Med: 177.12 Max: 366.94
Current: 435.63
103.07
366.94
Days Sales Outstanding 262.82
SVA's Days Sales Outstanding is ranked lower than
93% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. SVA: 262.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
SVA' s 10-Year Days Sales Outstanding Range
Min: 11.25  Med: 176.39 Max: 244.46
Current: 262.82
11.25
244.46

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 6.71
SVA's Price/Net Current Asset Value is ranked higher than
54% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. SVA: 6.71 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SVA' s 10-Year Price/Net Current Asset Value Range
Min: 2.06  Med: 5.98 Max: 50.13
Current: 6.71
2.06
50.13
Price/Tangible Book 2.22
SVA's Price/Tangible Book is ranked higher than
82% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. SVA: 2.22 )
Ranked among companies with meaningful Price/Tangible Book only.
SVA' s 10-Year Price/Tangible Book Range
Min: 0.9  Med: 2.48 Max: 14.04
Current: 2.22
0.9
14.04
Price/Median PS Value 1.04
SVA's Price/Median PS Value is ranked higher than
57% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. SVA: 1.04 )
Ranked among companies with meaningful Price/Median PS Value only.
SVA' s 10-Year Price/Median PS Value Range
Min: 0.29  Med: 1.04 Max: 4.26
Current: 1.04
0.29
4.26
Earnings Yield (Greenblatt) (%) 0.51
SVA's Earnings Yield (Greenblatt) (%) is ranked higher than
77% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. SVA: 0.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SVA' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.2  Med: 8.30 Max: 52.8
Current: 0.51
0.2
52.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SVQ.Germany,
Sinovac Biotech Ltd, formerly known as Net-Force System Inc., was incorporated in Antigua and Barbuda on March 1, 1999. The Company is an integrated China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A, hepatitis A and B, seasonal influenza, H5N1 and H1N1 pandemic influenza and mumps, as well as animal rabies vaccine. The Company is engaged in the development, manufacturing and sales of vaccines for infectious diseases. Its product consist of Healive, for the treatment of Hepatitis A; Bilive, for the treatment of Hepatitis A&B; Anflu, for the treatment of Influenza; Panflu Whole Viron Pandemic Influenza Vaccine, for Pandemic Influenza Virus; Split Viron Pandemic Influenza Vaccine, for the treatment of Pandemic Influenza Virus; Panflu.1, for the treatment of Influenza A H1N1 virus; RabEnd, for the treatment of Rabies Virus in animals; Mumps Vaccine, for the treatment of mumps; EV71 Vaccine, Pneumococcal Polysaccharide Vaccine, Varicella Vaccine, for the treatment of varicella-zoster virus, H7N9 Vaccine, for the treatment of H7N9 influenza. The Company has four manufacturing bases located in Haidian and Changping Districts of Beijing, Dalian City of Liaoning Province, and Tangshan City of Hebei Province and also has two upstream production facilities in Haidian District, Beijing. It has built a new production site in in Changping District, Beijing, which comprises a new filing and packaging line that complies with the new PRC GMP standards, EV71 production facilities and a warehouse. The Company relies on its sales force to sell its products directly to CDCs in the private market. As of December 31, 2013, the in-house sales and marketing team consisted of 170 staff members located in 31 provinces throughout China. The Company obtains the raw materials from local and overseas suppliers. It maintains two suppliers for each key raw material, with the exception of hepatitis B antigens for Bilive production. The hepatitis B antigens are sourced from Beijing Temple of Heaven. The Company competes with Kunming Institute of Biological Product, Pukang Biological Co., Ltd., Changchun Institute of Biological Products and Changchun Changsheng Life Sciences Ltd for hepatitis A vaccine. It competes with Hualan Biological Engineering Inc., Changchun Institute of Biological Products, GSK, Aleph Biological Co., Ltd. and Zhejiang Tianyuan for influenza vaccines. The Company is subject to PRC laws and regulations governing the use, manufacture, storage, handling or disposal of hazardous materials and waste products.
» More Articles for SVA

Headlines

Articles On GuruFocus.com
Sernova Grants Stock Options Jun 26 2015 
Simavita Limited: Results of Government SIM(R) Trial in Denmark Apr 20 2015 
Simavita Limited: Cleansing Notice Under Section 708A the Corporations Act 2001 (Cth) and Under ASIC Apr 09 2015 
Simavita Limited: Release of Securities from Escrow Jan 20 2015 
Sernova to Participate in Biotech Showcase(TM) 2015 Healthcare Conference in San Francisco Jan 12 2015 
Simavita Appoints New Chairman Jan 07 2015 
Simavita Limited: Record Sales Reported and Canadian Market Update Jan 06 2015 
Simavita Limited: Results From 2014 Annual General and Special Meeting Dec 03 2014 
Simavita Expands Board of Directors by Appointing Craig Holland and Adds Appointment to Upcoming Sha Nov 14 2014 
Sernova Provides Corporate Update Nov 10 2014 

More From Other Websites
Q1 2015 Sinovac Biotech Ltd Earnings Release - Before Market Open May 15 2015
Sinovac Reports Unaudited First Quarter 2015 Financial R... May 14 2015
Sinovac Reports Unaudited First Quarter 2015 Financial Results May 14 2015
Sinovac Receives Site Inspection Notification for EV71 V... May 14 2015
Sinovac Receives Site Inspection Notification for EV71 Vaccine Production Facilities May 14 2015
Sinovac to Participate in UBS Global Healthcare Conferen... May 12 2015
Sinovac to Participate in UBS Global Healthcare Conference May 12 2015
Sinovac to Host Conference Call to Report First Quarter ... May 07 2015
Sinovac to Host Conference Call to Report First Quarter 2015 Unaudited Financial Results May 07 2015
Sinovac Files 2014 Annual Report on Form 20-F Apr 29 2015
Q4 2014 Sinovac Biotech Ltd Earnings Release - Before Market Open Apr 20 2015
Sinovac Reports Unaudited Fourth Quarter and Full Year 2... Apr 20 2015
Sinovac posts 4Q profit Apr 20 2015
Sinovac posts 4Q profit Apr 20 2015
Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results Apr 20 2015
Sinovac to Host Conference Call to Report Fourth Quarter... Apr 10 2015
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2014 Unaudited Financial... Apr 10 2015
Sinovac to Participate in China Medical and Healthcare Investment Conference Mar 18 2015
Sinovac Provides Updates on Pipeline Vaccines Mar 17 2015
Sinovac Provides Updates on Pipeline Vaccines Mar 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK